Article
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
Gastroenterology - 1 Aug 2005
von Wagner Michael, Huber Miriam, Berg Thomas, Hinrichsen Holger, Rasenack Jens, Heintges Tobias, Bergk Alexandra, Bernsmeier Christine, Häussinger Dieter, Herrmann Eva, Zeuzem Stefan
Abstract excerpt
BACKGROUND & AIMS: Standard therapy of patients with chronic hepatitis C virus (HCV) infected with HCV genotype-2 or -3 is the combination of pegylated interferon-alpha and ribavirin for 24 weeks. Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rates is unknown. METHODS: Patients chronically infected with HCV-2 (n = 39), HCV-2/3 (n = 1), or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.